Background-TMPRSS2-ERG gene fusions are frequently found in prostate cancer and are pathognomomic for prostatic origin. In a series of cancer cases assayed with comprehensive genomic profiling (CGP) in the course of clinical care, we reviewed the frequency of TMPRSS2-ERG fusions in patient tumors of various histologic subtypes.
BACKGROUND
Chromosomal translocations involving TMPRSS2, an androgen-regulated gene encoding a transmembrane serine protease, and members of the ETS transcription factor family including ERG, are frequently observed in prostate cancer. [1] Specifically, TMPRSS2-ERG fusions occur in approximately half of all prostate cancers and are believed to be a critical player in prostate carcinogenesis. [2] TMPRSS2-ERG is involved in the promotion of cell migration, invasion, and tumor progression. [1, 3] The prognostic and predictive value of TMPRSS2-ERG fusions is still under active investigation; however, some studies have suggested an association of the fusion gene with higher recurrence risk and possibly even increased risk of prostate cancer-related death. [4] [5] [6] Clinically, TMPRSS2-ERG fusions can be detected in formalin fixed paraffin embedded tumor specimens through comprehensive genomic profiling (CGP) assays that employ nextgeneration sequencing technology. The wide availability of this technology allows for practicing clinicians to readily ascertain the presence of gene fusion events, such as those between TMPRSS2 and ERG, in patient tumors. The identification of TMPRSS2-ERG in a patient with known adenocarcinoma of the prostate does not yet trigger a change in therapy as there are currently no therapies available to target TMPRSS2-ERG. However, the presence of this fusion in a case where prostate cancer was not the diagnosis may dramatically alter the therapeutic approach.
Here we review a large database of patients with advanced cancers undergoing comprehensive genomic profiling in the course of clinical care to ascertain the frequency of TMPRSS2-ERG in both prostate cancer and cases carrying diagnoses of non-prostate cancer. An index case was identified to highlight the clinical impact of this approach.
METHODS
The methods employed for this analysis have been previously described. [7] In brief, formalin-fixed, paraffin-embedded slides or blocks from tumor samples were subjected to comprehensive genomic profiling (CGP) in a CLIA-certified, CAP-accredited, NYSregulated reference laboratory (Foundation Medicine, Inc.). At least 50 ng of DNA per specimen was extracted and next-generation sequencing was performed on hybridizationcaptured, adaptor ligation based libraries to high, uniform coverage (>500×) for all coding exons of 182-315 cancer-related genes and 14-28 genes commonly rearranged in cancer. Base substitutions, short insertions, deletions, copy number changes, gene fusions, and rearrangements were identified.
The CGP results from over 60000 cancer cases submitted to Foundation Medicine by December 31 2015 were used to determine the frequency of TMPRSS2-ERG fusions across histologic subtypes. Genomic profiles for an index case of prostate cancer with histologic evolution from prostatic adenocarcinoma to pure squamous cell carcinoma were identified and described. Specimens from the primary and recurrent metastatic prostate cancer adenocarcinoma as well as from metastatic squamous cell cancer were subjected to CGP. A metachronous carcinoid tumor obtained from the same patient served as a source of presumptive germline DNA. An evolutionary tree was inferred using the Neighbor-Joining method, with the branch lengths being proportional to the number of genomic alterations acquired on the corresponding branch. [8] The evolutionary analysis was conducted in MEGA7. [9] Approval for this study, including a waiver of informed consent and a HIPAA waiver of authorization, was obtained from the Western Institutional Review Board (Protocol No. 20152817)
RESULTS
The TMPRSS2-ERG fusion gene was detected exclusively in tumor samples obtained from male patients. Table 1 summarizes the frequency of TMPRSS2-ERG across tumor types with at least one TMPRSS2-ERG-positive case. Other tumor types, for which TMPRSS2-ERG was not found, accounted for most of the cases (n=59114) in the overall dataset ( Table  2 ). TMPRSS2-ERG was present in 30% (250/825) of specimens classified histologically as prostate cancer. The prostate cancer histologic subtypes with the fusion gene included acinar adenocarcinoma (n=214; 29.9% of cases), neuroendocrine carcinoma (n=18; 35.3%), undifferentiated carcinoma (n=11; 27.5%) and ductal adenocarcinoma (n=7; 36.8%). In the 2,139 patients with carcinoma of unknown primary, 28 (1.3%) cases had TMPRSS2-ERG identified in their tumors and six of those were of the squamous cell subtype. TMPRSS2-ERG was also seen in undifferentiated small cell carcinoma of the lung (n=3; 0.9%) and in one lung squamous cell carcinoma tumor (n=1; 0.1%). The remaining TMPRSS2-ERGpositive cases had diagnoses of bladder urothelial carcinoma (n=2; 0.3%), bladder carcinoma not otherwise specified (n=2; 5.1%), pancreatic carcinoma not otherwise specified (n=1; 0.4%), or pancreatic neuroendocrine carcinoma (n=1; 0.1%).
The index case was a 75-year-old Caucasian male who was originally diagnosed in April 2009 with organ-confined prostate adenocarcinoma, Gleason 4+3 = 7. In June 2009, he underwent a robotic-assisted prostatectomy. He was noted to have a pT2 N0 Mx tumor; final histopathologic analysis identified his tumor to be of higher grade (Gleason 4+5=9). By November 2009 he was found to have a persistently detectable PSA of 0.2 later rising to 0.3 by January of 2010. The patient subsequently underwent salvage external beam radiation tomotherapy (64.8 Gy × 36 fractions) to the prostatic fossa. Despite radiation, his PSA continued to slowly rise over the next few years. In June of 2011, he had a liver biopsy for a very slowly enlarging liver nodule, which had been observed over the past 6 years. Histopathology of the liver biopsy was consistent with carcinoid tumor. Sandostatin LAR therapy initiated resulting in continued stabilization of the liver nodule and decline in serum chromogranin level. In March 2015, the patient developed obstructive uropathy from a large 5 cm left pelvic mass in the context of a rising PSA. Androgen deprivation therapy was initiated resulting in clinical benefit. Biopsy of the pelvic mass revealed pure squamous cell cancer (Figure 1 ). To palliate urinary and rectal obstruction from the enlarging pelvic mass, the patient underwent radical cystectomy with ileal conduit urinary diversion, low anterior resection with diverting colostomy, and small bowel resection in September 2015. The pelvic mass was confirmed to be pure squamous cell cancer. An incidental tumor deposit invading the small bowel was shown to be pure adenocarcinoma consistent with prostate cancer (Figure 1) . Unfortunately, the response to androgen deprivation therapy was transient, and the patient rapidly developed castration resistance.
CGP of all available tumor specimens was performed. Evolutionary relationships of the four specimens from the index patient are shown in Figure 2 . All three carcinoma specimens shared the TMPRSS2-ERG fusion, loss of PTEN exons 5-9, the TP53 missense mutation V147G, and variants of unknown significance in the genes PDGFRB (R177C) and PRKDC (S1660Y). In addition, the primary prostatic adenocarcinoma tumor (June 2009) carried high-level amplifications of the genes FOXP1 and TBX3, whereas the squamous cell carcinoma specimen (July 2015) and the prostatic adenocarcinoma metastasis (September 2015), which were both from the bladder, had homozygous loss of the adjacent genes CDKN2A and CDKN2B in common. The adenocarcinoma metastasis also harbored a subclonal NFE2L2 mutation (W8C), while the squamous cell carcinoma carried a distinct variant of unknown significance (CIC G133C). No reportable genomic alterations were identified in the benign carcinoid specimen; all of its variants were of unknown significance, shared with the other specimens, and had variant allele frequencies consistent with germline status. In summary, comprehensive genomic analysis identified truncal prostatic adenocarcinoma drivers in the squamous cell carcinoma, including the unexpected TMPRSS2-ERG fusion event, and thus indicated that the squamous cell carcinoma had arisen from a prostatic adenocarcinoma.
DISCUSSION
Prostate cancer is a highly heterogeneous malignancy on the genomic level. Nevertheless, morphologic evaluation of prostate cancer overwhelmingly identifies this tumor type to be adenocarcinoma, albeit of varying grades within the same tumor (intrapatient) or across different patient tumors (interpatient). Here we report an index case of prostate cancer with variant histology, specifically squamous cell carcinoma that was realized by the identification of TMPRSS2-ERG fusion in both the squamous (divergent histology) and in the primary prostatic adenocarcinoma specimen. To contextualize this observation, we employed a large dataset of various solid tumors that have undergone comprehensive genomic profiling as part of clinical decision making.
We observed TMPRSS2-ERG fusions in approximately 30% of prostate cancers which were predominantly adenocarcinoma, but the frequency of fusion-positive cases held true across histologic prostate tumor types. TMPRSS2-ERG fusion was also detected in advanced cancer cases carrying the diagnosis of non-prostate tumors as defined by the treating team. In addition to the index case of squamous carcinoma presented above, five additional patients who had squamous cell cancer were found to harbor TMPRSS2-ERG, a finding with likely therapeutic implications. Since TMPRSS2-ERG expression is primarily androgen receptor-driven, it is presumably a marker for potential sensitivity to androgen deprivation therapy. In the absence of genomic information, a histologic phenotype not known to be associated with prostate cancer, such as squamous cell carcinoma, would trigger a different treatment algorithm such as cytotoxic platinum-based chemotherapy. Interestingly, in a study of ERG gene rearrangements in small cell carcinoma of the prostate -a tumor type in which platinum-based chemotherapy is commonly used -the rate of ERG rearrangements was reported to be similar to that of prostatic acinar carcinomas [11] . Thus, the presence of a TMPRSS2-ERG fusion in a non-adenocarcinoma context ought to stimulate investigations into the role of androgen receptor pathway-directed therapy in combination with other systemic agents (including cytotoxic chemotherapy), perhaps as part of an innovative n-of-1 clinical trial or in preclinical studies of various combination treatment strategies in patientderived xenograft mouse models of TMPRSS-ERG expression non-adenocarcinoma.
Primary squamous cell carcinoma of the prostate has been previously reported in the literature but it is exceedingly rare. [10] Such cases may represent transformation of an prostatic adenocarcinoma primary, as in this index case. CGP for the index patient first established the correct clinical diagnosis and later revealed the pattern of clonal evolution and selection. Most importantly, the finding of TMPRSS2-ERG in the squamous cell tumor provided support for the use of androgen deprivation therapy for the patient.
There are important limitations to this analysis. Our report focuses solely on TMPRSS2-ERG fusions. Although this event represents the vast majority of ETS rearrangements, TMPRSS2 can be rearranged with other biologically relevant partner genes that were not specifically studied here and that could be similarly pathognomonic for a prostatic origin of advanced cancer in men. In addition, the relevance and impact of specimen source (primary or metastatic site) or disease state (e.g., castration sensitive versus refractory) could not be suitably controlled for in this descriptive study.
In conclusion, CGP should be considered in appropriately selected cases of metastatic cancer in men where the anatomic site of origin is uncertain as there are potential therapeutic implications. The evolutionary tree was inferred using the Neighbor-Joining method [8] , with the branch lengths being proportional to the number of genomic alterations acquired on the corresponding branch. Evolutionary analyses were conducted in MEGA7 [9] . Table 2 Tumor types for all 59,114 cases in the dataset
Tumor type
Percent of all samples (female and male)
Lung adenocarcinoma 12%
Colon adenocarcinoma 8%
Breast invasive ductal carcinoma 5%
Breast carcinoma (NOS) 5%
Unknown primary adenocarcinoma 3%
Brain glioblastoma 3%
Lung non-small cell lung carcinoma (NOS) 3%
Pancreas ductal adenocarcinoma 3%
Ovary serous carcinoma 3%
Lung squamous cell carcinoma 2%
